Synthetic Biology Market Growing With Rise In Medical

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 17, 2017 at 3:00 PM 65

Synthetic Biology Market Growing With Rise In Medical Demand - IndustryARC

Hyderabad, India, March 17, 2017 (GLOBE NEWSWIRE) -- The report “ Synthetic Biology Market: By Tool (XNAS, Chassis Organisms) By Technology (Bioinformatics, DNA sequencing, integrated systems) By Products (Core products, Enabled Products) By Application (Agriculture, Food, Biofuel, Medicine)-Forecast (2016- 2021) ”, published by IndustryARC, estimates that the advent of new manufacturing techniques and sources driven by a soaring healthcare industry, makes America a prime market area.

Browse numerous Market Tables and Figures spread through 153 Pages and an in-depth TOC on “ Synthetic Biology Market 2016-2021 ” http://industryarc.com/Report/15142/synthetic...arket.html

Scope & Regional Forecast of the Synthetic Biology Market:

Synthetic biology can be regarded as an emerging multi-disciplinary field which has potential to transform global industries like health, energy and environment to improve national growth and create job opportunities. It includes design and construction of new biological parts, systems and devices or to re-engineer the existing biological systems to meet the current issues. It could propose the solution for the growing environmental challenges, climatic changes and scarcity of pure water. Various approaches to synthetic biology involve minimal genome, xenobiology, protocells and DNA synthesis.

Request Sample PDF Brochure @ http://industryarc.com/pdfdownload.php?id=15142

This report explains the synthetic biology market which is segmented on the basis of tool, products, technology and application. The product segment is categorized into enabling products, core products and enabled products. Furthermore, based on the application, the market has been segmented into agriculture, medicine, chemical, food, biofuel and few others. The global blowing agents market is anticipated to grow extensively during the forecast period of 2017-2021.

Inquiry before buying report @ http://industryarc.com/inquiry-before-buying.php?id=15142

Prominent Segmentations Involved in the Synthetic Biology Market: The Synthetic Biology Market can be broken down into various segmentations on the basis of:

Tool: Xeno-Nucleic Acids (Xnas), Chassis Organisms, Oligonucleotides, Cloning Technology Kits, Enzymes.
Products: Enabling Products, Core Products, Enabled Products.
Technology: Bio informatics Technologies, DNA sequencing, Genome Engineering, Microfluidics Technologies, Biological Components, Integrated Systems, Pathway Engineering, Synthetic Microbial Consortia, Biofuel Technologies, Next Generation Sequencing, Nanotechnology, Cloning and Sequencing and Others.
Application: Agriculture, Biofuel, Medicine, Environmental Application, Chemical, Food, Industrial Enzyme, Biological Electrics, Personal Care and Others.
Geography: Americas, Europe, Asia-Pacific and Rest of the World (RoW).

Some of the sample companies profiled in the Synthetic Biology Market report are as follows:

BioAmber
Codexis, Inc.
DNA2.0, Inc.
Evolva
GEN9 Inc.
GeneArt (Life Technologies)
Green Biologics Limited
Halozyme
Invista
Twist Bioscience
Verdezyne
Ziopharm
Thermo Fisher Scientific, Inc.
Novozymes

Why buy this report?

Get a detailed picture of the Synthetic Biology Market.
Pinpoint growth sectors and identify factors driving change.
Understand the competitive environment, the market’s major players and leading brands.
A five-year forecast method is used in order to assess how the market is predicted to develop.

Purchase Synthetic Biology Market Report @ http://industryarc.com/purchasereport.php?id=15142

Browse Related Reports:

Cell Culture Market -By Type (Primary cell culture, Secondary cell culture) By Industry (Research Institutes, Biotechnology Companies, Pharmaceutical Companies) By Application (Bio Technology, Cancer Research, Tissue Culture & Others) -Forecast (2016-2021) http://industryarc.com/Report/15167/cell-culture-market.html Knockout Mice Model Market -By Type(Constitutive, Conditional, Safe & Other Knockouts) Technology (Homologous Recombination, Flex, Others) Service (Custom Mouse, Rat, Cell & Other Models) Application(Humanization Of Target Genes, Monitoring Biomarker Expression, Others)–Forecast(2016-2021) http://industryarc.com/Report/15098/knockout-...arket.html

About IndustryARC:

IndustryARC is a research and consulting firm that publishes more than 500 Reports Annually in various industries, such as Agriculture, Automotive, Automation & Instrumentation, Chemicals and Materials, Energy and Power, Electronics, Food & Beverages, Information Technology, Life sciences & Healthcare.

IndustryARC primarily focuses on Cutting Edge Technologies and Newer Applications of the Market. Our Custom Research Services are designed to provide insights on the constant flux in the global demand-supply gap of markets. Our strong analyst team enables us to meet the client research needs at a very quick speed with a variety of options for your business.

We look forward to support the client to be able to better address customer needs; stay ahead in the market; become the top competitor and get real-time recommendations on business strategies and deals. Contact us to find out how we can help you today.

Media Contact

Mr. Sanjay Matthews Business Development Manager Email: sales@industryarc.com Contact Sales: 1-614-588-8538 (Ext-101) Connect with us on LinkedIn - https://www.linkedin.com/company/industryarc Know more about IndustryARC Events: http://industryarc.com/events.php

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ascletis Targets Obesity with New FDA Submission

Breaking Ground with Innovative Obesity Treatment In the world of biotech, where breakthroughs are hard-fought and the stakes can seem insurmountable, Ascletis Pharma is swinging for the fences with their latest maneuver. They've submitted an Investigational New Drug application to the U.S. Food and Drug Administration for ASC30_39 FDC—a pioneering fixed-dose combo pill...

CREB Unlocks 8.50% APY Bonds for IRA Investors

CRET Broadens the Path to Fixed-Income Security If you're the type who gets a rash just thinking about stock market jitters, pay attention: Compound Real Estate Bonds (CREB) has cracked the door open a bit wider for your retirement peace of mind. They've teamed up with Equity Trust to offer their rock-solid 8.50% APY bonds through self-directed IRAs. That's right—these...

HanAll F&B Maps Bold U.S. Entry with Strategic Pivot

Diving into Uncharted Waters HanAll F&B is setting its sights on the U.S. market, a move that could be make-or-break for this South Korean food manufacturer. With their recent rebranding from Taebaek Sanchae Naengmyeon Farming Association, they're not just changing names—they're shifting operational gears. The name might sound new, but the gutsy ambition behind it is as...

Hansa Bolsters Financials with SERB Deal, Eyes Growth

Financial Gains and Strategic Shifts Oh, here we go again—another quarterly report from Hansa Biopharma, and this one’s got some meat on its bones. They’ve sparked up their financial engine with a hefty €115 million licensing deal with SERB, which is a real shot in the arm. As any investor worth their salt would see, this isn’t just about piling cash. It's...

Brent Crude's Tumult: Oil Giants Weather Market Shifts

Oil Market Faces Uncertain Waves The energy sector's a rough sea these days, with Brent crude prices yo-yoing close to that $100 mark. If you're looking for clarity, don't hold your breath—the EIA's latest report suggests we’re sticking near this price for the foreseeable future before easing into more palatable waters come late 2027. But we ain't there yet, as U.S....

Viatris Engages Investors at Key Healthcare Conferences

Viatris Steps Into the Limelight Across Conferences Investors, listen up—Viatris Inc. is about to spill some beans at a trio of high-stakes healthcare gatherings. Set to rub elbows with the who's who of the biopharma world, this global healthcare crusader's on a mission. They're lining up to have face time at the UBS Global Biopharma Conference, the Jefferies Global...

MOUZ Triumphs at IEM-Beijing 2026, Powered by AutoFull

A Showdown in Beijing: Esports at Its Peak IEM Beijing 2026 wrapped up on November 8, lighting up the Bloomage Biotech•Biohyalux ECM Arena with some high-octane Counter-Strike 2 matches. In a region that's nothing short of a digital battleground, Team MOUZ clinched the crown. And yeah, they didn't just do it solo; they did it seated in style on AutoFull chairs, the...

Modaxo Bolsters Public Transport Support for UITP 2027

Modaxo Steps Up for UITP Summit Hamburg 2027 Well, Modaxo's back at it again, laying down roots in the public transport sector. Fresh off the press, they've announced they'll be a Platinum Partner for the UITP Summit in Hamburg 2027. That's not just a handshake for the cameras, folks. It's a clear shout-out about where they see themselves in this industry. Living Their...

Nielsen's $1.4B Notes to Fuel Bold DoubleVerify Buy

Reading Between the Financial Lines Nielsen's latest move throws a hefty $1.4 billion worth of senior secured notes into the market, aimed at scooping up DoubleVerify in a play that’s as daring as it is dicey. It's the kind of gamble you discuss with your coffee buddy, sipping something strong enough to wake the dead, and exactly the kind of deal that gets seasoned...

PMET's Lithium-Tantalum Study Ups Stakes in Québec Project

Elevated Ambitions in Québec: PMET's Lithium-Tantalum Leap PMET Resources just handed us an intriguing update on their Shaakichiuwaanaan project up in Québec. They're reshaping the roadmap to crank out both lithium and tantalum more efficiently than a bear on a honeycomb. The revised feasibility study has put to paper numbers that have optimists—and skeptics...